Medicare AdvantageCoverageMedium impact
MA08.116d, Eptinezumab-jjmr (VYEPTI™)
Independence Blue Cross·Neurology, Family Medicine, Internal Medicine·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.116d for Eptinezumab-jjmr (VYEPTI™) has been reissued with an effective date of May 28, 2025. This is a pharmacy policy update that may affect coverage or prior authorization requirements for this migraine prevention medication.
Action Required
Before May 28, 2025: Billing team should review the complete policy document at the provided URL to identify specific changes to coverage criteria, prior authorization requirements, or billing procedures for Eptinezumab-jjmr (VYEPTI™). Update billing software and prior authorization workflows accordingly based on the full policy details.